Latest News
Improving quite markedly. two years ago, aducanumab was written off as a failure and the trial aldo was taking part in was abandoned. but the manufacturers, biogen, analysed more data and concluded those on the highest doses had better cognition, memory and language. this is the brain of someone with early alzheimers. the red areas show a build—up of amyloid, a protein which can form toxic deposits. this is the same individual after a year of aducanumab. significant amounts of amyloid have bee...
Source: news source